MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy

Table 2

Association between mpMRI and tumor characteristics in patients with positive repeat prostate biopsy (n = 75) or in patients with both repeat prostate biopsy and radical prostatectomy (n = 30).

	Gleason Grade Group, GGG					Clinical or Pathological T-stage			Total
	GGG 1	GGG 2	GGG 3	GGG 4	GGG 5	T1	T2	T3
Patients with positive repeat prostate biopsy (n = 75)
PI-RADS 1-2	11; (50.0%)	5; (22.7%)	0; (0.0%)	4; (18.2%)	2; (9.1%)	16; (72.7%)	6; (27.3%)	0; (0.0%)	22
PI-RADS 3	2; (13.3%)	6; (40.0%)	1; (6.7%)	3; (20.0%)	3; (20.0%)	0; (0.0%)	15; (100.0%)	0; (0.0%)	15
PI-RADS 4-5	3; (7.9%)	11; (28.9%)	6; (15.8%)	8; (21.1%)	10; (26.3%)	0; (0.0%)	28; (73.7%)	10; (26.3%)	38
Total	16; (21.3%)	22; (29.3%)	7; (9.3%)	15; (20.0%)	15; (20.0%)	16; (21.3%)	49; (65.3%)	10; (13.3%)	75
Patients with both repeat prostate biopsy and radical prostatectomy (n = 30)
PI-RADS 1-2	4; (30.8%)	2; (15.4%)	4; (30.8%)	1; (7.7%)	2; (15.4%)	-	8; (61.5%)	5; (38.5%)	13
PI-RADS 3	0; (0.0%)	4; (80.0%)	0; (0%)	0; (0.0%)	1; (20.0%)	-	3; (60.0%)	2; (40.0%)	5
PI-RADS 4-5	0; (0.0%)	1; (8.3%)	3; (25.0%)	4; (33.3%)	4; (33.3%)	-	6; (50.0%)	6; (50.0%)	12
Total	3; (10.0%)	8; (26.7%)	7; (23.3%)	5; (16.7%)	7; (23.3%)	-	17; (56.7%)	13; (43.3%)	30

PI-RADS: Prostate Imaging Reporting and Data System.